<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02725086</url>
  </required_header>
  <id_info>
    <org_study_id>DA3030_NP_I</org_study_id>
    <nct_id>NCT02725086</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A Randomized, Open-label, Two-way Crossover, Open-label Clinical Trial to Compare
      Pharmacokinetic/Pharmacodynamic Properties and Safety after Subcutaneous Administration of
      Leucostim® and Neupogen® in Healthy Adult Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf of Filgrastim</measure>
    <time_frame>0~48 hr</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Filgrastim</measure>
    <time_frame>0~48 hr</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUEC0-t of ANC(absolute neutrophil count)</measure>
    <time_frame>0~120 hr</time_frame>
    <description>PD parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emax of ANC(absolute neutrophil count)</measure>
    <time_frame>0~120 hr</time_frame>
    <description>PD parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of Filgrastim</measure>
    <time_frame>0~48 hr</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of Filgrastim</measure>
    <time_frame>0~48 hr</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Filgrastim</measure>
    <time_frame>0~48 hr</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Filgrastim</measure>
    <time_frame>0~48 hr</time_frame>
    <description>PD parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC0-t of CD34+ cell count</measure>
    <time_frame>0~312 hr</time_frame>
    <description>PD parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emax of CD34+ cell count</measure>
    <time_frame>0~312 hr</time_frame>
    <description>PD parameter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1; Filgrastim 5 ㎍/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 5 ㎍/kg or Neupogen®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 2, Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2; Filgrastim 10 ㎍/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neupogen®(Filgrastim) 10 ㎍/kg or Leucostim®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 10 ㎍/kg or Neupogen®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 2, Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucostim®</intervention_name>
    <arm_group_label>Part 1; Filgrastim 5 ㎍/kg</arm_group_label>
    <arm_group_label>Part 2; Filgrastim 10 ㎍/kg</arm_group_label>
    <other_name>DA-3030</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neupogen®</intervention_name>
    <arm_group_label>Part 1; Filgrastim 5 ㎍/kg</arm_group_label>
    <arm_group_label>Part 2; Filgrastim 10 ㎍/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19 - 45 years

          -  BMI 18.5 - 25.0 kg/m2

          -  Value of ANC(absolute neutrophil count) had to be inside the normality range at the
             screening

        Exclusion Criteria:

          -  Subjects with a history or presence of clinically relevant hypersensitivity reaction
             to investigational drugs (G-CSF) or their ingredients/additives

          -  Subjects with a clinically relevant history of allergic reaction

          -  Subjects with a history of acute infectious diseases within 2 weeks prior to
             administration of investigational products

          -  At the investigator's discretion, subjects who is considered inappropriate to
             participate in the study due to any conditions including screening results
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <state>Seodamun-gu</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

